Navigation Links
Alexion Reports First Quarter 2008 Results
Date:4/30/2008


Growing Awareness of PNH Drives Strong Demand for Soliris(R) in U.S. and

Europe

First Non-GAAP Profit; Sales Guidance Revised Upward

Pipeline Progress in Neurology and Cancer

First Quarter 2008 Financial Highlights:

- Soliris(R) (eculizumab) net product sales were $45.5 million in Q1 2008,

compared to net product sales of $33.9 million in Q4 2007.

- Q1 GAAP net loss was $4.2 million, or $0.11 net loss per share, compared

to a GAAP net loss of $12.3 million, or $0.33 net loss per share, in

Q4 2007.

- Q1 non-GAAP net income was $1.6 million, or $0.04 net income per share,

compared to a non-GAAP net loss of $8.5 million, or $0.23 net loss per

share, in Q4 2007.

CHESHIRE, Conn., April 30 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced financial results for the quarter ended March 31, 2008.

First Quarter 2008 Financial Results:

For the three months ended March 31, 2008, Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") reported total revenues of $45.6 million compared to total revenues of $6.3 million for the same period in 2007. First quarter 2008 revenues were primarily from net product sales of Soliris(R) (eculizumab): $45.5 million, compared to $1.0 million in the first quarter of 2007 and $33.9 million in the fourth quarter of 2007. Soliris, approved by the U.S. Food and Drug Administration (FDA) in March 2007 and the European Commission (EC) in June 2007, is the only drug specifically indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria ("PNH"), a rare, debilitating and life-threatening blood disea
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Alexion to Present at Bear Stearns Healthcare Conference
2. Alexion Pharmaceuticals Invites You to Participate in its Fourth Quarter and Full Year 2007 Results Conference Call and Web Cast
3. Alexion Acquires All Rights to OMRF Patents Related to Soliris(R)
4. Alexion Reports Fourth Quarter and Full Year 2007 Results
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. QMed, Inc. Reports July Medicare SNP Enrollments
7. Phlo Affiliate Reports Expanded Coverage to Oregon Border
8. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Carrington Reports Second Quarter 2007 Results
11. Avitar Reports Third Quarter Financial Results for Fiscal 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014 Budding Biomedical Scientists , ... School participated in the Scientific Enrichment and ... School of Medicine . , The ... professional experience in the sciences and brings them ... and students for both academic and career mentoring. ...
(Date:8/26/2014)... 2014 The 20 ambassadors representing the ... community issued the following statement on Facebook today regarding ... driving new funding specifically for ALS research: , “Who ... some ice would raise all this awareness and funding ... and on behalf of the entire ALS community, would ...
(Date:8/26/2014)...  ViveBio, LLC a leading provider of products ... announced today that it has signed a distribution ... Knoxville, Tennessee to distribute ... United States . ViveST is the first ... biological specimen transport systems.  The technology enables easy, ...
(Date:8/26/2014)... (PRWEB) August 26, 2014 Genedata, ... drug discovery and life science research, today announced ... will be held in Asia, Europe, and ... global pharmaceutical companies and leading research organizations will ... best practices, case studies, and upcoming challenges in ...
Breaking Biology Technology:Students at Cleveland's University School Conduct Biomedical Research at Case Western Reserve University’s School of Medicine 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 3ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 4ViveBio and Laboratory Procurement Services Sign Agreement for Distribution of the ViveST Line of Products 2Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings 2Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings 3
... Presented at 21st North American Cystic Fibrosis ... Findings in Adult population -, SOUTH PLAINFIELD, ... Inc.,(PTC), a biopharmaceutical company focused on the discovery, ... today announced encouraging data,from a Phase 2 clinical ...
... RIDGE, N.J., Oct. 5 VioQuest,Pharmaceuticals (OTC Bulletin ... acquiring, developing and,commercializing targeted cancer therapeutics, announced today ... Thursday, October 11, 2007 at 2:00 p.m.,Pacific Time ... Room in San Francisco.,Daniel Greenleaf, VioQuest,s president and ...
... SOMERSET, N.J., Oct. 5 Alfacell Corporation,(Nasdaq: ACEL ... call and,Webcast at 11 a.m. EDT on Monday, Oct. ... executive officer, and Lawrence A. Kenyon,executive vice president, chief ... Alfacell,s financial performance for the fiscal,fourth quarter and year ...
Cached Biology Technology:PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis 2PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis 3PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis 4PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis 5VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco 2VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco 3Alfacell to Host Fiscal Fourth Quarter and Year-End 2007 Financial Results Conference Call and Webcast 2
(Date:8/27/2014)... Africa is entering what is described by the Volunteer ... The Eastern Cape provincial government warned residents in ... strong winds and veld fires. A high veld ... and along the coast in the Great Kei and ... regions, and during thunderstorms. The thunderstorms bring lightning ...
(Date:8/27/2014)... deadly disease that exists as five strains, none of ... strains is the Sudan ebolavirus (SUDV). Although not the ... illness, even as recently as 2012. In a new ... , researchers now report a possible therapy that could ... Dye, Sachdev Sidhu, Jonathan Lai and colleagues explain that ...
(Date:8/27/2014)... Thousands of fishing traps are lost or abandoned each ... as derelict traps, which continue to catch fish, crabs, ... in losses to habitat, fisheries, and the watermen who ... to a newly published NOAA study. , The report, ... the first of its kind to examine the derelict ...
Breaking Biology News(10 mins):Potential therapy for the Sudan strain of Ebola could help contain some future outbreaks 2NOAA's Marine Debris Program reports on the national issue of derelict fishing traps 2
... A person,s ability to battle viruses at the cellular ... prions misfold and cluster native proteins to cause disease, ... marks the first discovery of so-called "good" prion-like proteins ... proteins involved in innate immunity: the way the body ...
... University professor is helping students improve their confidence ... learning. Candice Shoemaker, professor of horticulture, has ... and self-efficacy. Self-efficacy involves student confidence in understanding ... learning and achievement. Shoemaker,s published research appeared in ...
... be a leading cause of the decline of coral reefs ... Georgia have found that extreme low temperatures affect certain corals ... potentially catastrophic consequences for coral ecosystems. Their findings appear in ... Biology . Lead author Dustin Kemp, a postdoctoral associate ...
Cached Biology News:'Good' prion-like proteins boost immune response, UT Southwestern scientists report 2Finding their way: Study shows connection between academic direction and student learning 2Finding their way: Study shows connection between academic direction and student learning 3Study: Severe low temperatures devastate coral reefs in Florida Keys 2Study: Severe low temperatures devastate coral reefs in Florida Keys 3
... Have you bought a Perkin Elmer UltraVIEW system ... the Andor iXon and iQ software? No problem. ... upgrade. You keep your existing microscope, lasers, Sutter ... customise it to work with our precision controller ...
...
... is a 96-well ELISA-compatible plate (containing 12 x ... Monoclonal Antibody is immobilized by a method that ... the tail fiber protein of the T7 bacteriophage. ... 10 9 phage per well and low ...
... The TRAPeze RT Telomerase Detection ... in vitro assay for the ... quantification of telomerase activity. It ... TRAPeze assay and adds the ...
Biology Products: